ONCOLYTICS BIOTECH COMPLETES ENROLLMENT IN COMBINATION REOLYSIN/RADIATION TRIAL

A A

Oncolytics Biotech has completed patient enrollment in its Phase Ia clinical trial investigating the use of Reolysin in combination with radiation to treat patients with advanced cancers.

A total of 11 patients were treated in the Phase Ia trial with two intratumoural treatments of Reolysin at several dosages with a constant localized radiation dose of 20 Gy in five fractions. A maximum tolerated dose was not reached and the combination treatment appears to have been well-tolerated by the patients.